BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/18/2025 7:43:21 AM | Browse: 159 | Download: 459
 |
Received |
|
2024-12-28 10:25 |
|
Peer-Review Started |
|
2024-12-28 10:25 |
|
First Decision by Editorial Office Director |
|
2025-02-20 02:41 |
|
Return for Revision |
|
2025-02-20 02:41 |
|
Revised |
|
2025-02-27 01:56 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-03-13 02:33 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-03-13 03:09 |
|
Articles in Press |
|
2025-03-13 03:09 |
|
Edit the Manuscript by Language Editor |
|
2025-03-18 00:17 |
|
Typeset the Manuscript |
|
2025-04-14 03:04 |
|
Publish the Manuscript Online |
|
2025-04-18 07:43 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Rethinking carnitine palmitoyltransferase-II and liver stem cells in metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hong Cai, Chun-Hui Yang and Peng Gao |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Peng Gao, PhD, Professor, Department of Clinical Laboratory, The Second Hospital of Dalian Medical University, No. 467 Zhongshan Road, Dalian 116023, Liaoning Province, China. gaop@dmu.edu.cn |
| Key Words |
Metabolic dysfunction-associated fatty liver disease; Carnitine palmitoyltransferase-II; Hepatocellular carcinoma; Liver cancer stem cells; Mitochondrial dysfunction; Metabolic dysfunction |
| Core Tip |
This article reviews a recent study by Wang et al investigating how carnitine palmitoyltransferase-II inactivity drives malignant progression in metabolic dysfunction-associated fatty liver disease through aberrant lipid metabolism, T-cell dysfunction, and liver cancer stem cells activation. Their work revealed that mitochondrial damage and reduced carnitine palmitoyltransferase-II activity under lipid-rich conditions may be early indicators of liver cancer risk, influencing immune cell profiles and the stem cell-like properties of hepatocytes. Understanding these processes could pave the way for novel preventative and therapeutic interventions targeting the metabolic and immunological underpinnings of metabolic dysfunction-associated fatty liver disease-related hepatocarcinogenesis. |
| Publish Date |
2025-04-18 07:43 |
| Citation |
Cai H, Yang CH, Gao P. Rethinking carnitine palmitoyltransferase-II and liver stem cells in metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma. World J Gastroenterol 2025; 31(15): 104528 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i15/104528.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i15.104528 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
